Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

At the start of this year, I observed that shares of Gilead Sciences, Inc. (NASDAQ:GILD) saw a downward re-rating after the ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Heal ...

Gilead Sciences ( (GILD) ) has released its Q3 earnings. Here is a breakdown of the information Gilead Sciences presented to its investors.

(RTTNews) - Gilead Sciences Inc. (GILD) released earnings for third quarter that decreased from last year but beat the Street estimates. The company's earnings came in at $1.253 billion, or $1.00 per ...

Gilead Sciences (GILD) has been one of the most searched ... While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and ...

Shares of Gilead Sciences Inc. GILD slipped 1.36% to $96.57 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.38% to 5,995. ...

Represents Gilead’s revenue from cobicistat (“C”), FTC and TAF in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.

(RTTNews) - Gilead Sciences Inc. (GILD) released earnings for third quarter that decreased from last year but beat the Street estimates. The company's earnings came in at $1.253 billion ...